香雪制药(300147) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥568,856,745.84, a decrease of 3.37% compared to ¥588,724,855.57 in the same period last year[4] - The net profit attributable to shareholders was -¥35,659,979.04, representing a significant decline of 886.00% from a profit of ¥4,536,891.13 in the previous year[4] - The basic earnings per share were -¥0.05, a drop of 600.00% from ¥0.01 in the previous year[4] - Net profit for Q1 2024 was a loss of CNY 28,629,807.17, compared to a profit of CNY 8,281,817.19 in the same period last year[20] - The total comprehensive income for Q1 2024 was a loss of CNY 28,625,879.70, compared to a gain of CNY 3,899,115.34 in the same period last year[22] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 53.05%, amounting to ¥25,813,931.15 compared to ¥54,977,540.05 in the same period last year[4] - The company's cash and cash equivalents decreased to CNY 117,268,682.42 from CNY 149,316,999.85, reflecting a decline of approximately 21.5%[15] - The ending balance of cash and cash equivalents was 103,037,097.49 CNY, down from 135,223,408.72 CNY at the beginning of the period, indicating a decrease in liquidity[23] - The company received 12,800,000.00 CNY in cash from borrowings, a decrease from 42,950,000.00 CNY in the previous period, suggesting tighter credit conditions[23] - Cash outflow for repaying debts was 10,370,000.00 CNY, compared to 28,441,661.27 CNY in the previous period, indicating a reduction in debt repayment obligations[23] - The company distributed dividends and interest payments totaling 38,492,874.71 CNY, down from 44,261,720.18 CNY in the previous period, reflecting a potential strategy to conserve cash[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,240,218,479.11, a slight decrease of 0.49% from ¥8,280,629,979.39 at the end of the previous year[4] - The equity attributable to shareholders decreased by 1.85%, amounting to ¥1,889,045,772.00 compared to ¥1,924,701,823.57 at the end of the previous year[4] - The company's total liabilities decreased slightly to CNY 5,955,206,531.83 from CNY 5,967,412,152.41[21] - The total current liabilities decreased to CNY 5,152,530,199.12 from CNY 5,161,681,554.89, showing a reduction of about 0.2%[17] Operational Challenges - The company is facing liquidity issues, leading to disputes over loan contracts and the freezing of 110,422,897 shares, which represents 16.70% of the total share capital[13] - The company has initiated debt restructuring strategies, including asset sales and bank loan extensions, to optimize its debt structure[14] - The company is actively seeking support from local government and regulatory bodies to facilitate debt restructuring and financial assistance[14] Other Financial Metrics - Total operating revenue for Q1 2024 was CNY 568,856,745.84, a decrease of 3.0% from CNY 588,724,855.57 in the previous year[19] - Total operating costs increased to CNY 591,588,915.65, up 0.1% from CNY 587,997,301.38[19] - Research and development expenses for Q1 2024 were CNY 17,327,643.17, slightly down from CNY 17,941,867.46[19] - The company reported a cash flow impact from exchange rate changes of 46.22 CNY, contrasting with -54,629.23 CNY in the previous period, suggesting a stabilization in foreign exchange effects[23] - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[24]